Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management ...

Edesa Biotech has announced its participation in upcoming conferences, including BIO-Europe in Vienna and the LSX Investival Showcase in London. This participation highlights Edesa’s ongoing efforts ...

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (KNE:CA) (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its ...

MAIA Biotechnology, Inc. ( ($MAIA) ) has provided an update. On October 27, 2025, MAIA Biotechnology announced its participation in the 2025 ...

A webcast replay of the discussion will be available from the Investors section of the company’s website at www.iobiotech.com for 30 days. A webcast replay of the discussion will be available from the ...

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, ...

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple international conferences, highlighting its focus on ...

“Clinical conferences are an opportunity for Kane to reinforce our innovation in wound care,” said Dr. Robert Huizinga, Interim CEO. “These presentations are an expansion of our market support plan ...

Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or ...

Bristol-Myers Squibb Co BMY's sBLA for its Opdivo-Yervoy combination for treating adults with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer that has ...

Cylembio ® (imsapepimut and etimupepimut, adjuvanted) is an investigational, immune-modulatory, off-the-shelf therapeutic cancer vaccine candidate designed to kill both tumor cells and ...